HYTN Innovations has announced that wholesale cannabis products previously exported to Germany during the prior quarter have now been successfully released for sale in the German market.
The release follows completion of required import, quality control, and market release procedures for Germany's regulated medical cannabis market. Following this milestone, the Company has accepted a reorder for additional wholesale product.
"The successful release of product into the German market is a significant commercial milestone," said Elliot McKerr, Chief Executive Officer of HYTN. "It validates that our GMP platform meets the stringent requirements of one of the world's most tightly regulated medical cannabis markets. The acceptance of a reorder is a positive indicator as we continue toward building recurring international revenue channels."
HYTN believes the successful German market release of this shipment further validates the commercial progress reflected in its recent financial results and supports the Company's strategy of expanding pharmaceutical-grade cannabis sales into highly regulated international markets.
For more information:
HYTN Innovations
hytn.ca/
